Published online Aug 10, 2015. doi: 10.4239/wjd.v6.i9.1092
Peer-review started: January 22, 2015
First decision: March 6, 2015
Revised: June 25, 2015
Accepted: July 21, 2015
Article in press: July 23, 2015
Published online: August 10, 2015
Processing time: 205 Days and 22.7 Hours
Core tip: Vasculopathy and cardiovascular (CV) manifestations in patients with type 2 diabetes differ dependent on disease duration. This literature review supports that it is necessary to contextualize results of CV outcome trials in diabetes to diabetes duration as well as duration and mode of action of the intervention, which may be of particular relevance for those interventions that primarily target pathways related to atherosclerotic processes, organ-remodelling, or vessel integrity. Several CV outcome trials testing newer therapy classes (i.e., di-peptidyl peptidase-4 inhibitors, glucagon-like protein-1 receptor analogues and sodium glucose co-transporter-2 inhibitors) are now due to report and a multiaxial approach to interpret these results is needed.